USD10
AVTX Shares
About Avalo TherapeuticsAvalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.

USD10
AVTX Shares
About Avalo TherapeuticsAvalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.

Stats

TRADING WINDOW

Closed

OPENS AT

Apr 14 at 1:30 PM GMT+0

MARKET CAP

$316.76M

OPEN PRICE

$13.56

LOW (1Y)

$3.39

HIGH (1Y)

$20.72

LOW (24H)

$13.15

HIGH (24H)

$14.07

VOLUME (24H)

$544.34K

8.98%

Price history

Time
Price
Change
Today
$13.56
2.51%
1 Day
$13.72
1.31%
1 Week
$16.19
14.14%
1 Month
$16.34
14.93%
1 Year
$4.90
183.67%
Past performance is not a reliable indicator of future results.

Discover more

Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.